(Q43960965)

28 November 2017

title

Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis (English)

1 reference

non-alcoholic steatohepatitis

28 November 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Nathalie Carvalho Leite

1

1 reference

28 November 2017

Gil Fernando Salles

2

1 reference

28 November 2017

Claudia Regina Lopes Cardoso

3

1 reference

28 November 2017

Cristiane Alves Villela-Nogueira

4

1 reference

28 November 2017

publication date

16 October 2012

1 reference

28 November 2017

1 reference

28 November 2017

volume

43

1 reference

28 November 2017

issue

5

1 reference

28 November 2017

page(s)

508-515

1 reference

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Inflammation and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Significance of serum adiponectin levels in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

CCN proteins: multifunctional signalling regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01106.X

10.1111/J.1872-034X.2012.01106.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference